Hengrui Pharma (01276) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "Company") held its 18th meeting of the 9th Board of Directors on August 20, 2025, where a proposal to repurchase the Company's A-shares via centralized bidding was reviewed and approved. The proposal authorized the Company to use its own funds to repurchase shares through centralized bidding transactions, intended for an A-share employee stock ownership plan.

The repurchase price is set not to exceed RMB 90.85 per share (inclusive), with a total repurchase amount of no less than RMB 1 billion and no more than RMB 2 billion. The repurchase period is within 12 months from the date the board approved the share repurchase proposal.

In January 2026, the Company repurchased 175,000 shares via the Shanghai Stock Exchange trading system using the centralized bidding method. These repurchased shares account for 0.003% of the Company's total share capital, with the highest purchase price at RMB 57.48 per share and the lowest at RMB 57.20 per share. The total amount paid was RMB 10.0386 million (excluding transaction fees).

As of January 27, 2026, the Company had cumulatively repurchased 9.0737 million shares under this buyback program through the Shanghai Stock Exchange trading system via centralized bidding. The cumulative repurchased shares represent 0.14% of the total share capital, with the highest purchase price at RMB 70.00 per share and the lowest at RMB 57.20 per share. The total amount paid has reached RMB 605 million (excluding transaction fees).